Skip to main content

At diagnosis of metastatic prostate cancer, many patients with HRR mutations remain

Unidentified1,2

Patients with HRR mutations are at risk

The presence of pathogenic HRR mutations, of which BRCA1 and BRCA2 are among the most common1, has been associated with an early onset of disease, aggressive tumour growth, higher recurrence, and poor prognosis3.

HRR: Homologous recombination repair

BRCA1: Breast cancer gene 1

BRCA2: Breast cancer gene 2

REFERENCES: 1. Teyssonneau D, Margot H, Cabart M, et al. J Hematol Oncol 2021;14(51):1-19.↵ 2. Robinson D, Van Allen EM, Wu Y, et al. Cell 2015;161(5):1215-1228.↵ 3. Scott RJ, Mehta A, Macedo GS, et al. Oncotarget 2021;12(16):1600-1614.↵ 

Please see our Privacy Policy and Terms & Conditions